Cedars Sinai
MitraClip confers mitral regurgitation reduction in two trials
Conquer Cancer Foundation presents Merit Awards at ASCO
Patient feedback can help ensure balance between cancer treatment efficacy, tolerability
ACC chair: New Orleans meeting to focus on ‘transforming’ CV care
Comparative study finds most effective bowel preps
Malnutrition common in IBD: Screen early, often to best care for patients
Investigators receive Laura Ziskin Prize in Translational Research
Second-generation IBS blood test available for commercial distribution

PHILADELPHIA – Gemelli Biotech, in cooperation with the Medically Associated Science and Technology Program at Cedars-Sinai, announced the availability of ibs-smart, a blood test for the diagnosis of irritable bowel syndrome, at the close of the American College of Gastroenterology Annual Scientific Meeting.
Q&A: Believing IBS is a disease of ‘nervous, anxious women’ is ‘antiquated’ and ‘wrong’
Interest expands as wearable technology advances

Researchers showed interest in the assessment of physical activity through step counters as early as the 1960s, but the practice was not accepted as scientific research until the 1990s. Wearable technology has come a long way since then and so has the overall interest in using these devices as research tools. Today, however, there are lingering questions regarding which information collected from such devices is most relevant and what should be done with it.